About This Program

This program aims to develop CD47 × PD-L1 therapeutic bispecific antibody for immuno-oncology.

Rationale when developing the program:

• CD47 and PD-L1, respectively, work as key innate and adaptive checkpoints.
• CD47 and PD-L1 checkpoints on tumor cells can coordinate to suppress immune sensing.
• Bispecific fusion proteins work better when targeting tumor cells than non-tumor cells.
• Dual-targeting of both checkpoints increases cytosolic DNA sensing in DCs to generate anti-tumor T cell responses.

In summary, combining therapy involves CD47 and PD-L1 may highlight a new outlook in cancer immunotherapy.

CD47 × PD-L1

The programmed death-ligand 1 (PD-L1, or CD274, B7-H1) is a key anti-phagocytic signal, i.e "don't find me" signal, to the adaptive immune system. Similarly, CD47 is the key "don't eat me" signal for the innate immune system and adaptive immune response regulators. Both CD47 and PD-L1 are overexpressed on the surface of cancer cells. This can up-regulate the expression of their own regulators, therefore escaping immune surveillance.

Recent studies have shown that:

• The dual-blockage of anti-CD47 and anti-PD-L1 benefits the treatment of melanoma and colon cancer.
• The feasibility of o-expressing oncogenic CD47 and PD-L1 for tumorigenesis is demonstrated.

Ongoing Clinical Trials

• Currently, as far as we know, NO bispecific anti-CD47 × PD-L1 antibody is being evaluated in a clinical trial. Accumulated preclinical data are emerging, may support the synergistic anti-tumor effects of this bispecific combination.
• With all the existing data, we believe this dual-targeting strategy will provide insights into tumor immunotherapy, allowing us to fight cancer more confidently. In an effort to optimally leverage CD47 × PD-L1-mediated immune response, our next-generation CD47 × PD-L1 targeted antibody program attempts to explore an optimal combination strategy - that is, how to exert the best anti-tumor effect while synergistically expressing CD47 × PD-L1 together.

Program Planning and Management

We have extensive knowledge of end-to-end program development. For each program, we are committed to delivering the final complete program to our clients within 1.5 years before entering the IND stage.

Cooperation

Creative Biolabs is looking for potential partners (include but not limit to major pharma or biotech firms) to develop CD47 × PD-L1 bispecific antibody program together. Our scientists are dedicated to bringing years of valuable experience to our partner and achieve a meaningful partnership together. For any partners interested in our Next-IO™ programs, Creative Biolabs welcomes collaboration. Here are two ways for your choice, and please contact us for more details.

1) Collaborate with us and co-develop the programs from the discovery phase to IND enabling. Costs will be shared.
2) Become a licensed candidate for our programs.

With our quality control protocol and knowledge of global regulatory requirements, we can help our partners advance their with more chance to succeed. Look forward to cooperating with you in the near future.

Reference

• Liu, X.; et al. Dual targeting of innate and adaptive checkpoints on tumor cells limits immune evasion. Cell reports. 2018, 24(8): 2101-2111.

For Research Use Only | Not For Clinical Use